A randomized controlled trial comparing safety and efficacy of carboplatin and paclitaxel plus or minus sorafenib (BAY 43-9006) in chemonaive patients with stage IIIB-IV non-small cell lung cancer (NSCLC)

Trial Profile

A randomized controlled trial comparing safety and efficacy of carboplatin and paclitaxel plus or minus sorafenib (BAY 43-9006) in chemonaive patients with stage IIIB-IV non-small cell lung cancer (NSCLC)

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Sorafenib (Primary) ; Carboplatin; Paclitaxel
  • Indications Non-small cell lung cancer; Squamous cell cancer
  • Focus Biomarker; Registrational; Therapeutic Use
  • Acronyms ESCAPE
  • Sponsors Bayer
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 22 Mar 2011 New source identified and integrated (Australian New Zealand Clinical Trials Registry).
    • 08 Mar 2010 Results published in the Journal of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top